Peregrine
peregrin team

OUR TEAM

A TEAM OF PROFESSIONALS WHO BUILT DISRUPTIVE HEALTHCARE COMPANIES FROM THE GROUND UP

Our team has been investing in global private life science opportunities drawing from decades of experience in the healthcare sector. Peregrines’ team includes venture capital professionals with backgrounds in investment and operations.

Prior to Peregrine’s establishment, our founders started and managed five startups of their own, providing the hands-on, real application experience that continues to guide our mentorship style.

OUR TEAM

EYAL LIFSCHITZ

Cofounder & Managing General Partner

BOAZ LIFSCHITZ

Cofounder & Managing General Partner

LIOR SHAHORY

General Partner

Elazer R. Edelman

Chairman of the Medical Advisory Board

TAMIR TAL

Venture Partner

TAL CARASSO

Venture Partner, Director of Investor Relations, Business Development

DAVID (DUDI) ELDAR

Venture Partner, CFO

SHIRAN TEHILA MASHIAH

Analyst

AMIT ALFASI

Marketing Communications and Investor Relations

Ruben Schächter

Investment Director & Head of Europe

EYAL LIFSCHITZ

Cofounder & Managing General Partner

Eyal Lifschitz is a business founder and entrepreneur with years of experience establishing and managing medical technology companies and their business development efforts. Eyal was involved as a founder and a manger in PharmaSys (acquired by Elan Corp. NYSE: ELN), ECR (acquired by AVX Corp. NYSE: AVX), Visioncare Ophthalmic Technologies, and BioControl Ltd. and as a director of Given Imaging (NASDAQ: GIVN).

Currently, Eyal serves as chairman in the Israeli Early-Stage Investors Association (IEI) & Technology Incubator Forum (ITIF) which promotes Israeli high-tech ventures in domestically and abroad. Eyal is also a founder and chairman of GamVeGam, a non-for-profit cooperation between the Israeli Ministry of Education and the Israeli high-tech industry, which aims encourage high tech professionals to become teachers in public schools.

He holds an LLB from the Academic Center for Law and Science.

BOAZ LIFSCHITZ

Cofounder & Managing General Partner

Boaz Lifschitz cofounded two biomedical device companies, Visioncare and BioControl. Prior to founding Peregrine, Boaz was an active investor in various medical and software start-up companies.

Boaz has served on the boards of Cartiheal, Mend.io, OutSense, Elbit Imaging (EMITF), Insightec, Gamida Cell (GMDA) and others. Currently, Boaz serves (or observes) on the boards of Magneto, Aleph Farms, Wanda Fish, BrainQ, Bluewhite and others.

He has extensive experience in taking start-up companies through their technological and business development and financing stages.

He holds a BSc from Bar-Ilan University, and an MSc from Boston University and Ben-Gurion University jointly.

LIOR SHAHORY

General Partner

Lior Shahory has been with Peregrine since 2005. Working closely with entrepreneurs to build successful companies, he contributes extensive experience in investments, due diligence, strategic planning, project management, and business development.

Lior serves as CEO of Peregrine’s Incentive tech incubator. Additionally, he served on the boards of Momentis, Restore, Eximo, Cordio, Valtech, Magneto, Mend.io, Marketyze, Endostream, and Eurekify. Prior to Peregrine, he served as deputy director of Israel’s Chief Scientist’s incubator program.

Lior holds a BA in economics and business management from the University of Haifa, and an MBA from Tel-Aviv University.

Elazer R. Edelman

Chairman of the medical advisory board

Elazer R. Edelman, M.D., Ph.D., is the Edward J. Poitras Professor in Medical Engineering and Science at MIT, Professor of Medicine at Harvard Medical School, and Senior Attending Physician in the coronary care unit at the Brigham and Women’s Hospital in Boston.

Dr. Edelman directs MIT’s Institute for Medical Engineering and Science (IMES) and Clinical Research Center (CRC) as well as the Harvard-MIT Biomedical Engineering Center (BMEC) – all dedicated to applying the rigors of the physical sciences to elucidate fundamental biologic processes and mechanisms of disease.

His research interests meld his medical and scientific training to better understand underlying biology for application towards improved clinical decision making and device design. Many of his findings have been or are now in clinical trial validation. More than 300 students and postdoctoral fellows have passed through Dr. Edelman’s laboratory enabling publication of over 680 original scientific articles and some 80 patents.

Dr. Edelman is a fellow of the American College of Cardiology, the American Heart Association, the Association of University Cardiologists, the American Society of Clinical Investigation, American Institute of Medical and Biological Engineering, the American Academy of Arts and Sciences, National Academy of Inventors, the Institute of Medicine/National Academy of Medicine, and the National Academy of Engineering.
He served as a member of FDA’s Science Board and an ORISE fellow in the FDA EIR. For his work bringing cardiovascular translational research to an international level of excellence, the Spanish Parliament and King Juan Carlos awarded Dr. Edelman with the Spanish Order of Civil Merit for his work.

TAMIR TAL

Venture Partner

Tamir Tal has been with Peregrine since 2005 and is involved in M&A, investments, growth finance, funding and structured transactions, as well as, serving as board member in some of Peregrine’s portfolio companies.

Additionally, Tamir also serves as CEO at Peregrine’s portfolio Company Cordio Medical, a non-invasive Congestive Heart Failure monitoring device, using only patient’s speech, sampled via his mobile device.

Earlier in his career, Tamir served as a corporate lawyer with Shiboleth LLP, where he focused on hi-tech sector securities transactions, IPO, M&A, and venture capital investments. He later served as COO at Neovasc Medical Ltd., a cardiovascular medical device company that developed the Neovasc Reducer™ for the treatment of refractory angina (NASDAQ: (NVCN) as well as COO at Geomage a leading provider of imaging solutions for the oil and gas industry.

He holds an LLB and an MBA, both from Tel Aviv University.

TAL CARASSO

Venture Partner, Director of Investor Relations, Business Development

Since joining the Peregrine team in 2011, Tal Carasso has been in charge of all aspects of interfacing with the fund’s investors. He plays an active role in Peregrine’s business development process during the raising process of Peregrine’s various funds as well as in screening potential new portfolio companies.

Tal holds an M.A. in organizational consulting, and a B.A. in communications and management, both from Israel’s College of Management Academic Studies (COLLMAN).

DAVID (DUDI) ELDAR

Venture Partner, CFO

Dudi Eldar joined Peregrine in 2008. Previously, he served as CFO of software company ObserveIT, which was sold for over $225M; as CFO of Proficiency, a software company with subsidiaries in the US, Germany, and France; as VP Finance & Administration at biotech company ID Gene, and as controller and internal auditor at AVX, where he formed part of the financial team that saw the company grow from 130 to over 550 employees.

He holds a BA in business from Tel Aviv’s College of Management and has been a Certified Public Accountant since 1996.

SHIRAN TEHILA MASHIAH

Analyst

As an analyst for Peregrine, Shiran Tehila Mashiah brings unique insight into the biomedical business landscape. She has served as a senior biomed grant consultant at FreeMind, a firm specializing in non-dilutive funding, where she researched over 150 proposals for drugs and medical devices, examining all development stages, from basic science to commercialization. Shiran is certified as a clinical research associate (CRA) and is a qualified academic medical lab worker with hands-on experience at Shaare Zedek Medical Center’s IVF unit.

She holds an MSc in molecular biology from the Weizmann Institute and an MBA in biomedical management from the Hebrew University.

AMIT ALFASI

Marketing Communications and Investor Relations

Amit joined Peregrine in 2019 and oversees all media communications and public relations activities on behalf of the fund. As part of her responsibility, Amit strengthens the relationships with the fund’s global investors and manages the marketing activity, and brand strategy efforts.

Integrating into Peregrine’s life science core activity was natural for Amit, she holds a B.Sc. in Nutrition science, and before joining Peregrine she managed healthcare programs at a Municipal Health Department.

She holds a BSc in nutrition science from Ariel University and an MBA in marketing from Bar-Ilan University.

Ruben Schächter

Investment Director & Head of Europe

Ruben Schächter is a multi-disciplinary expert with proven expertise in the development of start-ups and the expansion of established corporations through focused management, the formation of strategic alliances, and the deployment of forward-thinking initiatives.
A member of Peregrine since 2021, he is responsible for the sustained growth of Peregrine and its portfolio companies through M&A activities and investments, as well as deepening strategic cooperations and oversight of the European market.

Prior to joining Peregrine, Ruben managed the investment banking and business development of a European investment bank. He co-founded ACK, a private European investment consortium, and also served as a hands-on Strategic Advisor to a multitude of European and Israeli Asset Managers, Family Offices, and Funds.

Ruben holds a Bachelor of Law equivalent from the University of Zurich.